MGCD0103(Mocetinostat)

• Catalog No.: S1122
• CAS Number: 726169-73-9
• M. F.: C23H20N6O
• M. W.: 396.4445
• Storage: -20°C

SYNONYMS

• IUPAC name: N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
• IUPAC Traditional name: mocetinostat
• Synonyms: Mocetinostat

DATABASE IDS

• CAS Number: 726169-73-9

PROPERTIES

• Target: HDAC
• Salt Data: Free Base
• Solubility: DMSO
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Cancer

Biological Activity

• Description: MGCD0103 (Mocetinostat) is a potent HDAC inhibitor for HDAC1, HDAC2 and HDAC3 with IC50 of 0.15 μM, 0.29 μM and 1.66 μM, respectively.
• Targets: HDAC1; HDAC2; HDAC3
• IC50: 0.15 μM; 0.29 μM; 1.66 μM ^[1]
• In Vitro: MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. ^[1]
• In Vivo: MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. ^[1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. ^[2]
• Clinical Trials: Phase II clinical trial has been completed in patients with refractory chronic lymphocytic leukemia.

Protocol

• Protocol: Kinase Assay ^[1]
• HDAC enzyme assay in vitro: The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
• Protocol: Cell Assay ^[1]
• Cell Lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
• Concentrations: 0-60 μM
• Incubation Time: 72 hours
• Methods: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO₂. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC50.
• Protocol: Animal Study ^[1]
• Animal Models: Female CD-1 nude mice bearing H1437 tumors
• Formulation: PBS acidified with 0.1 M HCl or PEG400/0.2 M HCl saline, 40:60
• Doses: 80 mg/kg
• Administration: Administered via p.o.

References

• References: [1] Fournel M, et al. Mol Cancer Ther. 2008, 7(4), 759-768.
• References: [2] Cavasin MA, et al. Circ Res. 2012, 110(5), 739-748.

REFERENCES

• Fournel M, et al. Mol Cancer Ther. 2008, 7(4), 759-768.
• Cavasin MA, et al. Circ Res. 2012, 110(5), 739-748.